This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Antitrust litigation - AbbVie et al - Humira

A proposed class action has been filed accusing AbbVie, Amgen, Samsung Bioepis, Mylan, Mylan, Sandoz, Fresenius Kabi, Pfizer, and Momenta Pharmaceuticals of unlawfully restraining competition in the market for the drug Humira and its biosimilar competitors. The complaint claims AbbVie has created a “patent thicket” - securing over 100 patents designed solely to insulate Humira from competition - and entered into illegal agreements with the remaining companies to delay biosimilar entry in the US until at least 2023.

To add details to this Case File regarding legal or economic representatives, please contact editors@mlex.com.

Timeline

Parties

Get the inside track, with MLex

With a global network of expert journalists digging deep into the areas of risk that matter to your business and clients—and the highest standards of impartiality—you can have complete trust in MLex to keep you ahead of the regulatory curve.


  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from specialists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

TRY MLEX FREE FOR 14 DAYS

View the parties now

Already a subscriber? Click here to login